Want to see AU:NTI full AI Analyst Report?
Top Page
Neurotech International
(Sydney:NTI)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
▲(30.00% Upside)
Action:Reiterated
Date:08/29/26
The score is primarily constrained by weak financial performance: unstable revenue (including a drop to zero), sustained losses, and ongoing cash burn despite a debt-free structure. Technical indicators also point to soft momentum (negative MACD, sub-50 RSI, and price below the 50-day average). Valuation is limited by negative earnings (negative P/E) and no dividend yield provided.
Positive Factors
Debt-free balance sheet
Zero debt removes interest expense and near-term leverage pressure, giving the company more flexibility than a similarly loss-making biotech. This is a meaningful structural strength, although it does not eliminate the need to fund ongoing operating losses.
Negative Factors
Revenue sustainability risk
The return to zero annual revenue demonstrates that commercial sales are not yet reliable or recurring. This weak visibility makes it difficult to support the operating cost base internally and increases dependence on clinical progress and external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt removes interest expense and near-term leverage pressure, giving the company more flexibility than a similarly loss-making biotech. This is a meaningful structural strength, although it does not eliminate the need to fund ongoing operating losses.
Read all positive factors
Neurotech International (NTI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$21.01M
Dividend YieldN/A
Average Volume (3M)2.28M
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth-100.00%
EPS Growth50.49%
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,616,070,000
10 Day Avg. Volume4,499,796
30 Day Avg. Volume2,279,903
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)27.08
Price to Sales (P/S)0.00
P/FCF Ratio-3.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neurotech International Business Overview & Revenue Model
Company Description
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and com...
How the Company Makes Money
null...
Neurotech International Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.33M | 0.00 | 2.44M | 1.96K | 5.96K | 38.26K |
| Gross Profit | 8.02M | 0.00 | 2.44M | -5.87K | 4.21K | -535.21K |
| EBITDA | -8.72M | -11.33M | -10.74M | -8.24M | -8.98M | -3.36M |
| Net Income | -3.85M | -6.54M | -10.60M | -5.07M | -7.79M | -3.36M |
Balance Sheet | ||||||
| Total Assets | 6.81M | 2.75M | 3.24M | 12.21M | 5.31M | 2.02M |
| Cash, Cash Equivalents and Short-Term Investments | 6.34M | 2.39M | 3.03M | 11.63M | 5.03M | 1.90M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 932.85K | 2.14M | 285.74K | 314.70K | 1.35M | 592.98K |
| Stockholders Equity | 5.88M | 611.14K | 2.95M | 11.90M | 3.96M | 1.43M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -4.22M | -9.02M | -4.60M | -6.32M | -2.96M |
| Operating Cash Flow | -2.97M | -4.22M | -9.02M | -4.60M | -6.32M | -2.96M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.21K |
| Financing Cash Flow | 3.35M | 3.58M | 429.53K | 11.19M | 9.45M | 26.40K |
Neurotech International Technical Analysis
Negative
0.01
Price Trends
0.02
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
41.53
Neutral
-66.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NTI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.53 is Neutral, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NTI.
Neurotech International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$8.79B | 61.24 | 8.01% | 3.80% | -0.90% | -62.14% | |
61 Neutral | AU$50.94M | 250.00 | 0.93% | ― | 18.54% | ― | |
54 Neutral | AU$73.62M | -28.51 | -5.44% | ― | 2.73% | 25.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$160.81M | -19.72 | -46.84% | ― | ― | 20.40% | |
44 Neutral | AU$33.13M | -2.93 | -103.48% | ― | -22.43% | 15.02% | |
43 Neutral | AU$21.01M | -3.18 | -201.54% | ― | -100.00% | 50.49% |
* Healthcare Sector Average
AU:NTI
Neurotech International
0.01
>-0.01
-7.14%
AU:COH
Cochlear
136.45
-153.79
-52.99%
AU:CMP
Compumedics Limited
0.28
>-0.01
-1.79%
AU:SOM
Somnomed Limited
0.36
-0.39
-52.03%
AU:EMV
EMvision Medical Devices Ltd.
1.76
-0.25
-12.25%
AU:CBL
Control Bionics Ltd.
0.06
0.02
52.63%
Neurotech International Corporate Events
Neurotech Narrows Loss as R&D Grants Drive Revenue Surge
Aug 26, 2026
Neurotech International reported an 86% rise in revenues to $4.8 million for the year ended 30 June 2026, driven almost entirely by a substantial increase in RD grant income. Despite this uplift, the company remains loss-making, but narrowed its l...
Neurotech Elevates Mark Davies to Executive Chairman as Phase III Cannabinoid Program Advances
Aug 17, 2026
Neurotech International, a clinical-stage biopharmaceutical developer of cannabinoid-based therapies for paediatric neurological disorders, is advancing its lead oral drug candidate NTI164 through late-stage clinical development. The company’...
Neurotech Confirms Compliance as New Shares Enter Secondary Trading
Aug 11, 2026
Neurotech International Ltd is a clinical-stage biopharmaceutical company developing NTI164, an oral cannabinoid therapy for paediatric neurological and neuropsychiatric disorders, including Autism Spectrum Disorder, PANDAS/PANS and Rett Syndrome....
Neurotech International Seeks ASX Quotation for 293 Million New Shares
Aug 11, 2026
Neurotech International Limited has applied for quotation on the ASX of 293,328,277 ordinary fully paid shares, with an issue date of 11 August 2026. The new securities form part of previously announced transactions, signalling a substantial expan...
Neurotech raises $4.5m to fund pivotal ASD Phase III trial
Aug 3, 2026
Neurotech International has secured binding commitments for a $4.5 million share placement, bringing in existing and new institutional and sophisticated investors at an issue price of $0.014 per share. The capital raising strengthens the company&#...
Neurotech secures FDA IND nod and U.S. patent wins as autism drug program advances
Jul 31, 2026
Neurotech International’s June-quarter activities centred on advancing NTI164, with operational emphasis on the Phase 3 Beyond Harmony trial in paediatric autism and preparations for regulatory submissions in multiple markets. The company is...
Neurotech Autism Trial Data Secures Publication in Leading Neurotherapeutics Journal
Jul 29, 2026
Neurotech International has reported that data from its Phase II/III Harmony Study of NTI164 in children with autism spectrum disorder have been accepted for publication in Neurotherapeutics, a leading peer‑reviewed journal of the American S...
Neurotech taps $3.15m R&D tax loan to fund Phase III ASD trials
Jul 15, 2026
Neurotech International has secured a $3.15 million secured loan from Rockford RDF, providing non-dilutive financing backed by the company’s anticipated FY2026 and FY2027 refundable RD tax incentive offsets. The facility, carrying a 16% inte...
Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy
Jul 13, 2026
Neurotech International has secured U.S. FDA clearance for its Investigational New Drug application for NTI164, a CBDA-rich cannabinoid formulation targeting paediatric neurodevelopmental disorders. The decision establishes a formal U.S. clinical ...
Neurotech International Issues 19.5 Million New Unlisted Options
Jul 13, 2026
Neurotech International has notified the market of the issue of 19.5 million unquoted options across two new classes, exercisable at $0.02 and $0.03 and expiring in July 2028 and July 2029, respectively. The options issuance, recorded as of July 1...
Neurotech Wins Key U.S. Patent Allowances for NTI164 Autism Therapy
Jul 2, 2026
Neurotech International has received Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications covering key aspects of its NTI164 cannabinoid-based therapy for neurological disorders. One set of allowed claims cove...
Neurotech International Options Lapse, Reducing Potential Share Dilution
Jun 29, 2026
Neurotech International has confirmed the expiry and cessation of 5,000,000 options, previously on issue under the ASX code NTIAAE, which were scheduled to expire on June 28, 2026 with an exercise price of $0.10. The options lapsed unexercised, re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.